EAM Investors’s Syndax Pharmaceuticals SNDX Stock Holding History

EAM Investors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35,391	Closed	-$901K	–	352
2022 Q4	$901K	Sell	35,391 -16,777	-32%	-$391K	0.19%	235
2022 Q3	$1.25M	Buy	+52,168	New	+$1.17M	0.27%	158
2021 Q1	–	Sell	-70,666	Closed	-$1.57M	–	434
2020 Q4	$1.57M	Buy	+70,666	New	+$1.47M	0.26%	182

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

EAM Investors's SNDX Position: Q1 2023 in Review

EAM Investors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 35,391 shares — an estimated $901K sold.

EAM Investors first reported a position in SNDX in Q4 2020 and held it in 3 quarters. The position peaked at $1.57M in Q4 2020. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

EAM Investors reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 35,391 Syndax Pharmaceuticals shares in Q1 2023, an estimated $901K.
EAM Investors first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 3 quarters.
EAM Investors's Syndax Pharmaceuticals position peaked at $1.57M in Q4 2020.
163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.